Jhala N C, McFarland M M, Brightman S A, Morale B, Rubin W, Atkinson B F
Department of Pathology & Laboratory Medicine, Medical College of Pennsylvania, Philadelphia, USA.
Am J Gastroenterol. 1995 Oct;90(10):1824-8.
BACKGROUND/AIMS: Lansoprazole is a new potent proton pump inhibitor that exhibits activity against Helicobacter pylori in vitro. This study endeavored to determine the effects of 4 wk of lansoprazole therapy upon H. pylori infection and antral gastritis in duodenal ulcer patients and to determine the relationship of the gastritis with Helicobacter infection and with ulcer activity.
Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo. Sections were scored blindly for degree of active and chronic inflammation and extent of H. pylori infection.
Four weeks of lansoprazole (30 mg daily) or ranitidine (300 mg daily) therapy produced a significant decrease in H. pylori infection. The reduction of H. pylori infection, but not ulcer healing per se, correlated with the decrease in active and chronic antral inflammation. Reduction of H. pylori infection, however, did not improve the good ulcer-healing rates already achieved at 4 wk by potent acid inhibition.
Lansoprazole exhibits activity against H. pylori in vivo. Short-term improvement in antral gastritis is affected by reduction of H. pylori infection but not by ulcer healing.
背景/目的：兰索拉唑是一种新型强效质子泵抑制剂，在体外对幽门螺杆菌具有活性。本研究旨在确定兰索拉唑治疗4周对十二指肠溃疡患者幽门螺杆菌感染和胃窦炎的影响，并确定胃炎与幽门螺杆菌感染以及溃疡活动之间的关系。
从119例十二指肠溃疡患者中获取满意的胃窦活检组织，分别在接受兰索拉唑、雷尼替丁或安慰剂治疗4周前后进行取材。对切片进行盲法评分，以评估活动性和慢性炎症程度以及幽门螺杆菌感染范围。
兰索拉唑（每日30毫克）或雷尼替丁（每日300毫克）治疗4周后，幽门螺杆菌感染显著减少。幽门螺杆菌感染的减少，而非溃疡本身的愈合，与胃窦活动性和慢性炎症的减轻相关。然而，幽门螺杆菌感染的减少并未改善通过强效抑酸在4周时已达到的良好溃疡愈合率。
兰索拉唑在体内对幽门螺杆菌具有活性。胃窦炎的短期改善受幽门螺杆菌感染减少的影响，而非溃疡愈合的影响。
